Jones Trading Issues Pessimistic Forecast for Femasys (NASDAQ:FEMY) Stock Price

Femasys (NASDAQ:FEMY) had its target price trimmed by Jones Trading from $10.00 to $6.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright lowered their price objective on Femasys from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, May 9th.

Femasys Stock Up 1.9%

Shares of FEMY stock opened at $1.07 on Tuesday. Femasys has a one year low of $0.86 and a one year high of $1.80. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The stock has a fifty day moving average price of $1.26 and a 200 day moving average price of $1.23. The stock has a market cap of $29.15 million, a P/E ratio of -1.32 and a beta of -2.52.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.14 million. Analysts predict that Femasys will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Femasys

A number of hedge funds have recently made changes to their positions in FEMY. Geode Capital Management LLC boosted its position in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Femasys in the 4th quarter worth approximately $25,000. Dauntless Investment Group LLC acquired a new position in shares of Femasys in the 1st quarter worth approximately $1,969,000. Clear Creek Financial Management LLC grew its position in Femasys by 5.5% during the 1st quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock worth $338,000 after acquiring an additional 14,000 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Femasys during the 4th quarter valued at $45,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.